var data={"title":"Hypertriglyceridemia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hypertriglyceridemia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/contributors\" class=\"contributor contributor_credentials\">Robert S Rosenson, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/contributors\" class=\"contributor contributor_credentials\">John JP Kastelein, MD, PhD, FESC</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/contributors\" class=\"contributor contributor_credentials\">Mason W Freeman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertriglyceridemia is most often identified in individuals who have had a lipid profile as part of cardiovascular risk assessment. (See <a href=\"topic.htm?path=screening-for-lipid-disorders-in-adults#H7832879\" class=\"medical medical_review\">&quot;Screening for lipid disorders in adults&quot;, section on 'Choice of tests'</a> and <a href=\"topic.htm?path=cardiovascular-disease-risk-assessment-for-primary-prevention-our-approach\" class=\"medical medical_review\">&quot;Cardiovascular disease risk assessment for primary prevention: Our approach&quot;</a> and <a href=\"topic.htm?path=overview-of-established-risk-factors-for-cardiovascular-disease#H9\" class=\"medical medical_review\">&quot;Overview of established risk factors for cardiovascular disease&quot;, section on 'Lipids and lipoproteins'</a>.)</p><p>This topic reviews the evidence that hypertriglyceridemia contributes to the development of adverse cardiovascular events, the mechanisms by which this might occur, the disorders of triglyceride metabolism that have been identified, and recommendations for the management of hypertriglyceridemia. The pathways involved in triglyceride synthesis and metabolism are discussed separately. (See <a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis#H11\" class=\"medical medical_review\">&quot;Lipoprotein classification, metabolism, and role in atherosclerosis&quot;, section on 'Endogenous pathway of lipid metabolism'</a>.) The management of patients with hypertriglyceridemia who have acute or prior pancreatitis is also discussed separately. (See <a href=\"topic.htm?path=hypertriglyceridemia-induced-acute-pancreatitis\" class=\"medical medical_review\">&quot;Hypertriglyceridemia-induced acute pancreatitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H823705211\"><span class=\"h1\">INDICATIONS FOR MEASUREMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The indications for the measurement of serum triglyceride are presented separately. (See <a href=\"topic.htm?path=measurement-of-blood-lipids-and-lipoproteins#H24361278\" class=\"medical medical_review\">&quot;Measurement of blood lipids and lipoproteins&quot;, section on 'Indications for measurement'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DEFINITION AND PREVALENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In this topic, we categorize patients into one of the following four groups based on their fasting triglyceride level: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal &ndash; &lt;150 <span class=\"nowrap\">mg/dL</span> (1.7 <span class=\"nowrap\">mmol/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mild hypertriglyceridemia &ndash; 150 to 499 <span class=\"nowrap\">mg/dL</span> (1.7 to 5.6 <span class=\"nowrap\">mmol/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate hypertriglyceridemia &ndash; 500 to 886 <span class=\"nowrap\">mg/dL</span> (5.6 to 10.0 <span class=\"nowrap\">mmol/L)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Very high or severe hypertriglyceridemia &ndash; &gt;886 <span class=\"nowrap\">mg/dL</span> (&ge;10.0 <span class=\"nowrap\">mmol/L)</span></p><p/><p>To convert from <span class=\"nowrap\">mg/dL</span> to <span class=\"nowrap\">mmol/L,</span> divide by 88.5.</p><p>In this topic, when discussing management, we refer to the range of fasting triglyceride levels from 150 to 500 <span class=\"nowrap\">mg/dL</span> (1.7 to 5.6 <span class=\"nowrap\">mmol/L)</span> as &quot;mild to moderate&quot; hypertriglyceridemia and levels &ge;886 <span class=\"nowrap\">mg/dL</span> (10.0 <span class=\"nowrap\">mmol/L)</span> as &quot;severe&quot; hypertriglyceridemia. </p><p>Hyperlipidemia is common but varies with the population being studied. In the United States, the National Health and Nutrition Examination Surveys (NHANES) from 1999 to 2004 found that the percentage of adults with triglyceride levels above 150 <span class=\"nowrap\">mg/dL</span> (1.7 <span class=\"nowrap\">mmol/L),</span> 200 <span class=\"nowrap\">mg/dL</span> (2.3 <span class=\"nowrap\">mmol/L),</span> 500 <span class=\"nowrap\">mg/dL</span> (5.7 <span class=\"nowrap\">mmol/L),</span> and 1000 <span class=\"nowrap\">mg/dL</span> (11.3 <span class=\"nowrap\">mmol/L)</span> was 33, 18, 1.7, and 0.4 percent, respectively [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/1\" class=\"abstract_t\">1</a>]. &#160;</p><p>In individuals with established cardiovascular disease, the prevalence will be higher [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/2\" class=\"abstract_t\">2</a>]. Serum triglyceride values above 1000 <span class=\"nowrap\">mg/dL</span> (11 <span class=\"nowrap\">mmol/L)</span> occur in fewer than 1 in 5000 individuals [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">TRIGLYCERIDES AND CVD RISK</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Atherosclerosis is the most common underlying pathology in patients with cardiovascular disease (CVD). The effect of abnormal triglyceride metabolism on atherosclerosis has been studied by evaluating the incidence of coronary events, the contribution of triglyceride-containing lipoproteins to atherosclerosis progression, and the incidence of cerebrovascular ischemic events [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/3,4\" class=\"abstract_t\">3,4</a>]. These studies generally show a positive relationship between hypertriglyceridemia and atherosclerotic burden [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/5-9\" class=\"abstract_t\">5-9</a>].</p><p>Elevated triglyceride levels are independently associated with increased risk of CVD events [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/10,11\" class=\"abstract_t\">10,11</a>]. (See <a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis#H1824420\" class=\"medical medical_review\">&quot;Lipoprotein classification, metabolism, and role in atherosclerosis&quot;, section on 'Triglycerides'</a>.)</p><p>Mendelian randomization studies support a causal relationship [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/11\" class=\"abstract_t\">11</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one study, triglyceride-mediated pathways were found to be causally involved in coronary heart disease (CHD), though the study could not directly assess whether triglycerides themselves cause CHD [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/12,13\" class=\"abstract_t\">12,13</a>]; other genetic studies suggest that elevated triglyceride levels increase the risk of CHD [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/11,14-16\" class=\"abstract_t\">11,14-16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study that used multiple independent single nucleotide polymorphisms as variables (n= 62,199), unrestricted and restricted allele scores for triglycerides were associated with CHD events (odds ratio 1.62, 95% CI 1.24-2.11 and 1.61, 95% CI 1.00-2.59, respectively) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p>The following studies also demonstrate the association between hypertriglyceridemia and CVD events: &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a 2007 report of two large prospective studies, the combined adjusted odds ratio for CHD comparing individuals in the top third of serum triglyceride levels with those in the bottom third was 1.7 (95% CI 1.6-1.9) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/18\" class=\"abstract_t\">18</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a 2007 study of nearly 14,000 untreated younger males, aged 26 to 45 years who had serum triglycerides measured five years apart, triglycerides at first measurement were strongly and independently associated with CHD risk when comparing those in the highest quintile to those in the lowest (multivariate hazard ratio 4.1) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/19\" class=\"abstract_t\">19</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertriglyceridemia is associated with increased mortality in patients with known CHD, and both increased mortality and reduced event-free survival after coronary artery bypass graft surgery [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/20,21\" class=\"abstract_t\">20,21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two large studies found that increased nonfasting triglyceride levels are associated with an increased risk for ischemic stroke [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/22,23\" class=\"abstract_t\">22,23</a>]. (See <a href=\"topic.htm?path=overview-of-secondary-prevention-of-ischemic-stroke\" class=\"medical medical_review\">&quot;Overview of secondary prevention of ischemic stroke&quot;</a>.)</p><p/><p>One difficulty that has existed in establishing a causal role for hypertriglyceridemia in CHD is that it is associated with other abnormalities that predispose to atherosclerosis or are associated with increased CVD risk. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Low levels of high density lipoprotein cholesterol [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/24-32\" class=\"abstract_t\">24-32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small, dense low density lipoprotein particles [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/33-36\" class=\"abstract_t\">33-36</a>]. (See <a href=\"topic.htm?path=inherited-disorders-of-ldl-cholesterol-metabolism-other-than-familial-hypercholesterolemia#H22\" class=\"medical medical_review\">&quot;Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia&quot;, section on 'Small dense LDL (LDL phenotype B)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Atherogenic triglyceride-rich lipoprotein remnants [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/37,38\" class=\"abstract_t\">37,38</a>]. (See <a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis#H17\" class=\"medical medical_review\">&quot;Lipoprotein classification, metabolism, and role in atherosclerosis&quot;, section on 'Intermediate density lipoprotein (remnant lipoproteins)'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Insulin resistance [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/39,40\" class=\"abstract_t\">39,40</a>]. (See <a href=\"topic.htm?path=insulin-resistance-definition-and-clinical-spectrum\" class=\"medical medical_review\">&quot;Insulin resistance: Definition and clinical spectrum&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increases in coagulability and viscosity [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/41-43\" class=\"abstract_t\">41-43</a>]; triglyceride-mediated hyperviscosity may contribute to endothelial dysfunction, tissue ischemia, and the chylomicronemia syndrome (see below) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p>At least two studies have shown that increasing size and concentration of lipoproteins that carry triglycerides are associated with incident type 2 diabetes [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/44,45\" class=\"abstract_t\">44,45</a>]. In addition, elevated triglycerides (&gt;70 <span class=\"nowrap\">mg/dL)</span> predict incident diabetes. Large VLDL particle concentration is the lipoprotein subclass most strongly associated with future risk of type 2 diabetes.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CAUSES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypertriglyceridemia may occur in the setting of other diseases or treatments (acquired) or may be genetically based.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Acquired disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following acquired disorders, conditions, and therapies raise serum triglycerides and this change may be particularly pronounced in patients with underlying defects in triglyceride metabolism (<a href=\"image.htm?imageKey=PC%2F106983\" class=\"graphic graphic_table graphicRef106983 \">table 1</a>): </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obesity, often in association with an elevation in serum cholesterol [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"topic.htm?path=overweight-and-obesity-in-adults-health-consequences\" class=\"medical medical_review\">&quot;Overweight and obesity in adults: Health consequences&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diabetes mellitus, where there is a relationship to poor glycemic control and, in type 2 diabetes, obesity [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/47,48\" class=\"abstract_t\">47,48</a>]. (See <a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">&quot;Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nephrotic syndrome, often in association with hypercholesterolemia, and renal failure [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/49,50\" class=\"abstract_t\">49,50</a>]. (See <a href=\"topic.htm?path=lipid-abnormalities-in-nephrotic-syndrome#H5\" class=\"medical medical_review\">&quot;Lipid abnormalities in nephrotic syndrome&quot;, section on 'Hypertriglyceridemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypothyroidism, often in association with hypercholesterolemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=lipid-abnormalities-in-thyroid-disease#H4\" class=\"medical medical_review\">&quot;Lipid abnormalities in thyroid disease&quot;, section on 'Pathophysiology'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnancy. (See <a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-endocrine-and-metabolic-changes#H15\" class=\"medical medical_review\">&quot;Maternal adaptations to pregnancy: Endocrine and metabolic changes&quot;, section on 'Lipid metabolism'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Estrogen replacement administered orally. The elevation in serum triglycerides may not be seen with transdermal estrogen replacement [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/52\" class=\"abstract_t\">52</a>]. Estrogen in both oral and transdermal contraceptives may also increase serum triglyceride concentrations. (See <a href=\"topic.htm?path=menopausal-hormone-therapy-and-cardiovascular-risk\" class=\"medical medical_review\">&quot;Menopausal hormone therapy and cardiovascular risk&quot;</a> and <a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">&quot;Risks and side effects associated with estrogen-progestin contraceptives&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">Tamoxifen</a> can cause marked hypertriglyceridemia in a minority of women [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"topic.htm?path=managing-the-side-effects-of-tamoxifen#H9\" class=\"medical medical_review\">&quot;Managing the side effects of tamoxifen&quot;, section on 'Coronary heart disease'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta blockers, with the exception of <a href=\"topic.htm?path=carvedilol-drug-information\" class=\"drug drug_general\">carvedilol</a>, which has little effect on serum triglycerides. Alpha blockers lower serum triglycerides, while low-dose diuretics, angiotensin converting enzyme inhibitors, and calcium antagonists have little or no effect [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/54,55\" class=\"abstract_t\">54,55</a>]. (See <a href=\"topic.htm?path=antihypertensive-drugs-and-lipids\" class=\"medical medical_review\">&quot;Antihypertensive drugs and lipids&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunosuppressive medications, such as glucocorticoids and <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/56,57\" class=\"abstract_t\">56,57</a>]. The effect of glucocorticoids is associated with insulin resistance and appears to be mediated in part by suppression of corticotropin [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/56\" class=\"abstract_t\">56</a>]. (See <a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">&quot;Major side effects of systemic glucocorticoids&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HIV antiretroviral regimens [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/58\" class=\"abstract_t\">58</a>]. (See <a href=\"topic.htm?path=epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients#H2957194\" class=\"medical medical_review\">&quot;Epidemiology of cardiovascular disease and risk factors in HIV-infected patients&quot;, section on 'Dyslipidemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Retinoids. (See <a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris#H10\" class=\"medical medical_review\">&quot;Oral isotretinoin therapy for acne vulgaris&quot;, section on 'Other side effects'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3889979072\"><span class=\"h2\">Hereditary disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following disorders with a genetic basis are discussed in detail elsewhere:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chylomicronemia &ndash; Fasting chylomicronemia is characterized by triglyceride levels above the 99<sup>th</sup> (880 <span class=\"nowrap\">mg/dL</span> or 10 <span class=\"nowrap\">mmol/L)</span> percentile in association with a creamy plasma supernatant and cloudy infranatant due to increases in chylomicrons and very low density lipoprotein (VLDL) (<a href=\"image.htm?imageKey=PC%2F76826\" class=\"graphic graphic_picture graphicRef76826 \">picture 1</a> and <a href=\"image.htm?imageKey=CARD%2F54329\" class=\"graphic graphic_table graphicRef54329 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/59,60\" class=\"abstract_t\">59,60</a>]. The clinical manifestations include hepatosplenomegaly and occasional eruptive xanthomas. However, patients with marked hypertriglyceridemia (&ge;886 <span class=\"nowrap\">mg/dL</span> [10.0 <span class=\"nowrap\">mmol/L])</span> may develop the chylomicronemia syndrome. Manifestations of this disorder include recent memory loss, abdominal pain <span class=\"nowrap\">and/or</span> pancreatitis, dyspnea, eruptive xanthoma (<a href=\"image.htm?imageKey=PC%2F82268\" class=\"graphic graphic_picture graphicRef82268 \">picture 2</a>), flushing with alcohol, and lipemia retinalis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/61\" class=\"abstract_t\">61</a>]. </p><p/><p class=\"bulletIndent1\">Most patients have a secondary form in which some other dyslipidemia (eg, familial hypertriglyceridemia due to partial lipoprotein lipase [LPL] deficiency) is exacerbated by the administration of exogenous triglyceride-elevating therapies such as estrogen, <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>, glucocorticoids, or protease inhibitors [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/53,62\" class=\"abstract_t\">53,62</a>], or by poorly-controlled diabetes. There is also a primary form of type V hyperlipoproteinemia in which there is no deficiency in LPL or its ligand apo C-II [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/59,60\" class=\"abstract_t\">59,60</a>]. The underlying defect in this disorder is uncertain but apo E4, which is a ligand for the hepatic chylomicron and VLDL remnant receptor, may play a role [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/60\" class=\"abstract_t\">60</a>].</p><p/><p class=\"bulletIndent1\">Fasting chylomicronemia can be diagnosed by confirming the presence of chylomicrons and excess VLDL on agarose gel electrophoresis or ultracentrifugal analysis. A simple technique is to refrigerate plasma overnight and examine the specimen for a creamy supernatant from chylomicrons and a turbid VLDL-rich infranatant.</p><p/><p class=\"bulletIndent1\">This latter finding of a turbid infranatant is not seen in patients with type I hyperlipoproteinemia, in which only chylomicrons accumulate and the infranatant is clear. Patients with type I hyperlipoproteinemia generally have complete absence of either LPL activity (type Ia), apo C-II, lipoprotein maturation factor 1 (LMF1), apolipoprotein 5, or glycosylphosphatidylinositol-anchored high density lipoprotein (HDL) binding protein 1 [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/61,63,64\" class=\"abstract_t\">61,63,64</a>]. This is in contrast to partial LPL deficiency, where the type V phenotype (in which chylomicrons are present in the supernatant, and the infranatant is cloudy due to VLDL particles) is brought out by one of the exacerbating factors discussed above.</p><p/><p class=\"bulletIndent1\">Type Ia hyperlipoproteinemia is an extremely rare genetic disorder that results from homozygous deficiency in LPL activity. It is characterized by eruptive xanthomas, lipemia retinalis, and frequent episodes of pancreatitis. The only effective therapy has been a strict low-fat diet. A gene therapy for this condition, LPL(S447X) gene variant, in an adeno-associated viral vector of serotype 1 (alipogene tiparvovec [Glybera]), has been approved for use in Europe [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/65\" class=\"abstract_t\">65</a>], making it the first gene therapy approved for use in people. A study in three patients of an inhibitor of <em>APOC3</em> messenger RNA showed large reductions in triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/66\" class=\"abstract_t\">66</a>]; this finding was somewhat unexpected, as it had been presumed that the effects of apolipoprotein C3 (APOC3) on triglycerides were mediated by APOC3 inhibition of LPL.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial hypertriglyceridemia &ndash; Familial hypertriglyceridemia (type IV hyperlipoproteinemia phenotype) is an autosomal dominant disorder associated with moderate elevations in the serum triglyceride concentration (200 to 500 <span class=\"nowrap\">mg/dL</span> [2.3 to 5.6 <span class=\"nowrap\">mmol/L])</span>. It is often accompanied by insulin resistance, obesity, hyperglycemia, hypertension, and hyperuricemia.</p><p/><p class=\"bulletIndent1\">Patients with familial hypertriglyceridemia are heterozygous for inactivating mutations of the LPL gene and, as noted above, typically have low serum HDL-C (hypoalphalipoproteinemia) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/24,64\" class=\"abstract_t\">24,64</a>]. The common LPL mutations raise serum triglycerides by 20 to 80 percent [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/24\" class=\"abstract_t\">24</a>]. More marked elevations require some other factor such as one of the drugs or acquired disorders noted above, such as estrogen replacement therapy in postmenopausal women [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/62\" class=\"abstract_t\">62</a>]. (See <a href=\"#H9\" class=\"local\">'Acquired disorders'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial combined hyperlipidemia &ndash; Familial combined hyperlipidemia is a disorder caused by overproduction of hepatically-derived apolipoprotein B-100 associated with VLDL [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/67\" class=\"abstract_t\">67</a>]. (See <a href=\"topic.htm?path=inherited-disorders-of-ldl-cholesterol-metabolism-other-than-familial-hypercholesterolemia#H16\" class=\"medical medical_review\">&quot;Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia&quot;, section on 'Familial combined hyperlipidemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial dysbetalipoproteinemia &ndash; Familial dysbetalipoproteinemia (type III hyperlipoproteinemia) most often results from inheritance of two apo E2 alleles [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Premature coronary heart disease and peripheral vascular disease are common. Physical findings include tuberoeruptive xanthomas (<a href=\"image.htm?imageKey=PC%2F78663\" class=\"graphic graphic_picture graphicRef78663 \">picture 3</a>) and xanthomas of the palmar creases (xanthomata palmare striatum) (<a href=\"image.htm?imageKey=PC%2F58173\" class=\"graphic graphic_picture graphicRef58173 \">picture 4</a>). Laboratory findings are characterized by increased concentrations of triglyceride and cholesterol. An additional genetic or acquired factor that increases lipoprotein production or impairs lipoprotein removal is typically required for full clinical expression; examples include diabetes mellitus, hypothyroidism, obesity, or gout [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/68\" class=\"abstract_t\">68</a>]. (See <a href=\"#H9\" class=\"local\">'Acquired disorders'</a> above.) A similar effect is seen in an animal model of the disorder [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/70\" class=\"abstract_t\">70</a>].</p><p/><p class=\"headingAnchor\" id=\"H248234180\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with hypertriglyceridemia have no symptoms or signs associated with the biochemical abnormality. The following are exceptions:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with acquired disorders such as diabetes or obesity, clinical manifestations are usually due to the underlying disorder rather than the lipid abnormality.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with hereditary disorders, skin lesions such as xanthomas and xanthelasmas may be present. (See <a href=\"topic.htm?path=cutaneous-xanthomas#H597369408\" class=\"medical medical_review\">&quot;Cutaneous xanthomas&quot;, section on 'Clinical variants'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with very high triglyceride levels (above 1000 <span class=\"nowrap\">mg/dL</span> [11 <span class=\"nowrap\">mmol/L]),</span> pancreatitis may develop [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/71\" class=\"abstract_t\">71</a>]. It should be kept in mind that the diagnosis of triglyceride-mediated pancreatitis cannot be made in the absence of chylomicronemia. (See <a href=\"topic.htm?path=etiology-of-acute-pancreatitis#H10\" class=\"medical medical_review\">&quot;Etiology of acute pancreatitis&quot;, section on 'Hypertriglyceridemia'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-pancreatitis#H2\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of acute pancreatitis&quot;, section on 'Clinical features'</a> and <a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis#H3\" class=\"medical medical_review\">&quot;Lipoprotein classification, metabolism, and role in atherosclerosis&quot;, section on 'Chylomicrons'</a>.)</p><p/><p>The serum in patients with hypertriglyceridemia may be opalescent due to an increase in very low density lipoprotein; at higher levels, it may be milky due to hyperchylomicronemia. Most of these patients have one of the dyslipidemias described below with an additional condition known to raise serum triglycerides (eg, diabetes mellitus, alcohol abuse, or estrogen or <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> therapy) (<a href=\"image.htm?imageKey=PC%2F106983\" class=\"graphic graphic_table graphicRef106983 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/47,53,62\" class=\"abstract_t\">47,53,62</a>].</p><p class=\"headingAnchor\" id=\"H3925892135\"><span class=\"h1\">DIAGNOSTIC APPROACH</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For all patients who are found to have an elevated triglyceride level, an attempt should be made to identify a cause. In patients where a likely cause is not evident such as obesity or alcohol excess, we obtain a serum blood glucose, creatinine, and thyroid-stimulating hormone as well as a urinalysis <span class=\"nowrap\">(albumin/protein)</span>. If no secondary cause is evident, the patient likely has a hereditary cause. (See <a href=\"#H8\" class=\"local\">'Causes'</a> above.)</p><p class=\"headingAnchor\" id=\"H723637349\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are limited data regarding which patients with hypertriglyceridemia require treatment and which therapies provide the best outcomes. We recommend adoption of healthy lifestyle behaviors for all patients to lower cardiovascular risk and use lipid lowering therapies in some individuals to lower the risk of pancreatitis.</p><p class=\"headingAnchor\" id=\"H2126114411\"><span class=\"h2\">Lifestyle modifications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend adoption of lifestyle modifications similar to those recommended for individuals at high risk of cardiovascular disease. (See <a href=\"topic.htm?path=overview-of-primary-prevention-of-coronary-heart-disease-and-stroke#H3\" class=\"medical medical_review\">&quot;Overview of primary prevention of coronary heart disease and stroke&quot;, section on 'Major components'</a>.)</p><p>Hypertriglyceridemia is often induced or exacerbated by potentially correctable disorders [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/5,72\" class=\"abstract_t\">5,72</a>]. (See <a href=\"#H9\" class=\"local\">'Acquired disorders'</a> above.). Thus, nonpharmacologic interventions such as weight loss in obese patients; aerobic exercise; avoidance of concentrated sugars, alcohol, and medications that raise serum triglyceride levels; and strict glycemic control in diabetics should be first-line therapy [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/5,47,72\" class=\"abstract_t\">5,47,72</a>]. Other risk factors for cardiovascular disease, such as hypertension and smoking, should also be addressed.</p><p>A general discussion of the dietary approach to elevated lipid levels is found elsewhere. (See <a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements\" class=\"medical medical_review\">&quot;Lipid lowering with diet or dietary supplements&quot;</a>.) Appropriate dietary management of hypertriglyceridemia differs between mild-to-moderate and severe hypertriglyceridemia. Dietary management of mild-to-moderate hypertriglyceridemia should focus on &quot;eating less&quot; with a goal of weight loss, and also on reduction of carbohydrates, especially high glycemic and high fructose foods. Dietary fat is not a primary source for liver triglyceride, and higher fat diets do not raise fasting plasma triglyceride levels in most people. For patients with mild-to-moderate hypertriglyceridemia who are above their ideal body weight, we suggest a hypocaloric diet in combination with regular moderate-to-intense aerobic exercise. The diet should restrict consumption of high glycemic <span class=\"nowrap\">index/load</span> foods (<a href=\"image.htm?imageKey=PC%2F71978\" class=\"graphic graphic_table graphicRef71978 \">table 3</a>) as well as refined sugars, fruit juices, and high fructose beverages; we suggest increased consumption of fish that contain high amounts of omega-3 fatty acids (<a href=\"image.htm?imageKey=PC%2F79454\" class=\"graphic graphic_table graphicRef79454 \">table 4</a>).</p><p>At fasting triglyceride levels above 500 to 1000 <span class=\"nowrap\">mg/dL</span> (5.6 to 11.3 <span class=\"nowrap\">mmol/L),</span> the clearance of chylomicrons from the blood becomes very slow, such that chylomicrons from the previous night's meal are still present in morning fasting blood. This sets the stage for accumulation of chylomicron triglyceride derived from dietary fat, leading to a risk of pancreatitis and other manifestations of fasting chylomicronemia. Therefore, at very high fasting triglyceride levels (especially above 886 <span class=\"nowrap\">mg/dL</span> [10.0 <span class=\"nowrap\">mmol/L]),</span> it is crucial to restrict dietary fat greatly, to less than 25 to 40 g daily [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/73\" class=\"abstract_t\">73</a>]. Patients need to be reminded that even &quot;good fat&quot; such as vegetable oils and nuts, as well as fat contained in chips and pastries, can raise their triglyceride levels and cause pancreatitis. (See <a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements\" class=\"medical medical_review\">&quot;Lipid lowering with diet or dietary supplements&quot;</a>.)</p><p>Diets aimed at weight loss should be used cautiously, if at all, in patients with severe hypertriglyceridemia, and weight loss should generally be avoided until other therapies have reduced fasting triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/73\" class=\"abstract_t\">73</a>]. This is because when the weight-loss diet ends and refeeding begins, such patients are likely to develop very high triglyceride levels with a resultant increased risk of pancreatitis.</p><p>Alcohol overuse must be avoided in patients with severe hypertriglyceridemia, as it can cause large increases in triglyceride levels, which might precipitate pancreatitis. The effects of moderate alcohol consumption in patients with mild-to-moderate hypertriglyceridemia are less clear and may have only a limited effect on triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/74\" class=\"abstract_t\">74</a>]. This observation may be important in those with other risk factors for cardiovascular disease (CVD) in whom moderate alcohol consumption may improve coronary risk. (See <a href=\"topic.htm?path=cardiovascular-benefits-and-risks-of-moderate-alcohol-consumption\" class=\"medical medical_review\">&quot;Cardiovascular benefits and risks of moderate alcohol consumption&quot;</a>.) Given the potential risks of alcohol consumption in patients with hypertriglyceridemia, and while awaiting further study, we suggest that in patients with mild to moderate hypertriglyceridemia, men limit their alcohol consumption to no more than two drinks per day and women limit their consumption to no more than one drink per day.</p><p class=\"headingAnchor\" id=\"H1745689519\"><span class=\"h2\">Indications for drug therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The two potential indications for pharmacologic therapy to lower triglyceride levels are prevention of episodes of pancreatitis and lowering of cardiovascular risk. </p><p>For patients with triglyceride levels persistently above 886 <span class=\"nowrap\">mg/dL</span> (10.0 <span class=\"nowrap\">mmol/L),</span> we start drug therapy to lower the risk of pancreatitis. The rationale is that there is a risk of postprandial triglyceride elevations that may result in a triglyceride level &gt;1600 <span class=\"nowrap\">mg/dL</span> to 2000 <span class=\"nowrap\">mg/dL</span> in these individuals, levels that are associated with the development of pancreatitis. Although we are unaware of clinical trial data that specifically address this issue, we advise lowering triglyceride levels to less than 500 <span class=\"nowrap\">mg/dL</span>. We rarely treat at levels below 886 <span class=\"nowrap\">mg/dL</span> (10.0 <span class=\"nowrap\">mmol/L),</span> as the risk of pancreatitis from hypertriglyceridemia appears to be quite small [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/75-77\" class=\"abstract_t\">75-77</a>]. In patients with lower triglyceride levels, it is reasonable to consider drug therapy in patients with a prior episode of pancreatitis. (See <a href=\"topic.htm?path=hypertriglyceridemia-induced-acute-pancreatitis\" class=\"medical medical_review\">&quot;Hypertriglyceridemia-induced acute pancreatitis&quot;</a>.) &#160; </p><p>Despite the evidence linking hypertriglyceridemia to CVD risk (see <a href=\"#H3\" class=\"local\">'Triglycerides and CVD risk'</a> above), most of our contributors rarely start drug therapy to lower cardiovascular risk, as there is no strong evidence that targeting hypertriglyceridemia improves CVD outcomes. Studies have not clearly demonstrated an overall benefit of fibrates for reduction of cardiovascular or total mortality [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/78-80\" class=\"abstract_t\">78-80</a>].</p><p>In addition, most patients at increased CVD risk will have therapy, usually with a statin, targeting low density lipoprotein cholesterol (LDL-C). No trials of statins have looked specifically at patients with normal LDL-C and elevated triglycerides. High-intensity statin therapy is more effective than low-intensity statin therapy for lowering triglyceride levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/81\" class=\"abstract_t\">81</a>]. Among patients with triglycerides levels 200 <span class=\"nowrap\">mg/dL</span> to <span class=\"nowrap\">880/mg/dL,</span> <a href=\"topic.htm?path=atorvastatin-drug-information\" class=\"drug drug_general\">atorvastatin</a> 80 mg daily and <a href=\"topic.htm?path=rosuvastatin-drug-information\" class=\"drug drug_general\">rosuvastatin</a> 20 mg daily reduce fasting triglyceride levels by 43 to 44 percent [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/82,83\" class=\"abstract_t\">82,83</a>].<strong> </strong>Some of our contributors start high-intensity statin therapy, which can reduce triglycerides by about 40 percent, in patients with triglyceride levels above 500 <span class=\"nowrap\">mg/dL</span> and less than 886 <span class=\"nowrap\">mg/dL</span>. Their rationale is that statin therapy may reduce cardiovascular risk. (See <a href=\"topic.htm?path=management-of-elevated-low-density-lipoprotein-cholesterol-ldl-c-in-primary-prevention-of-cardiovascular-disease#H6\" class=\"medical medical_review\">&quot;Management of elevated low density lipoprotein-cholesterol (LDL-C) in primary prevention of cardiovascular disease&quot;, section on 'Indications'</a>.)</p><p>Several subgroup analyses of randomized trials performed in patients with coronary heart disease (CHD) or coronary risk equivalents raise the possibility that pharmacologic treatment targeting triglycerides, either alone or in combination with statins, could provide clinical benefit:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the Helsinki Heart Study, CHD risk was highest in the cohort with a triglyceride level &gt;201 <span class=\"nowrap\">mg/dL</span> (2.3 <span class=\"nowrap\">mmol/L)</span> and an <span class=\"nowrap\">LDL-C/HDL-C</span> ratio &gt;5.0 (<a href=\"image.htm?imageKey=CARD%2F67263\" class=\"graphic graphic_figure graphicRef67263 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/29\" class=\"abstract_t\">29</a>]. A benefit from <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> therapy was confined to this high-risk subgroup.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The VA-HIT trial assessed the efficacy of <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> therapy in patients with low HDL-C (&le;40 <span class=\"nowrap\">mg/dL</span> [1.0 <span class=\"nowrap\">mmol/L]),</span> relatively low LDL-C (&le;140 <span class=\"nowrap\">mg/dL</span> or 3.6 <span class=\"nowrap\">mmol/L),</span> and triglyceride levels &le;300 <span class=\"nowrap\">mg/dL</span> (3.4 <span class=\"nowrap\">mmol/L)</span> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/84\" class=\"abstract_t\">84</a>]. Gemfibrozil raised HDL-C by 6 percent, lowered triglycerides by 31 percent, and had no significant effect on LDL-C. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the ACCORD Lipid trial, fenofibrate showed no overall benefit when added to a statin in patients with type 2 diabetes, but tended to improve outcomes in the subset of patients with both elevated triglyceride levels (&gt;204 <span class=\"nowrap\">mg/dL</span> [2.30 <span class=\"nowrap\">mmol/L])</span> and low HDL-C levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/85\" class=\"abstract_t\">85</a>]. In an open label extension of the ACCORD and ACCORDION trials, fenofibrate therapy in statin-treated patients reduced the risk of CVD events [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/86\" class=\"abstract_t\">86</a>]. This subset analysis was pre-planned because of similar suggestions of benefit with fenofibrate in such subgroups that had previously been seen in the Helsinki Heart Study [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/29\" class=\"abstract_t\">29</a>], the FIELD trial [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/78\" class=\"abstract_t\">78</a>], and The <a href=\"topic.htm?path=bezafibrate-united-states-not-available-drug-information\" class=\"drug drug_general\">Bezafibrate</a> Infarction Prevention (BIP) trial [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/79\" class=\"abstract_t\">79</a>].</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Pharmacologic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As discussed above, the principal indication for pharmacologic therapy to lower triglyceride levels is to prevent pancreatitis in individuals with very high levels (&gt;886 <span class=\"nowrap\">mg/dL</span> [10.0 <span class=\"nowrap\">mmol/L])</span>. (See <a href=\"#H1745689519\" class=\"local\">'Indications for drug therapy'</a> above.) We start treatment with a fibrate other than <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> due to the common concurrent or potential later use of statins in many of these individuals.</p><p>Randomized trials have not directly compared agents for prevention of CVD events or pancreatitis in patients with hypertriglyceridemia. In the absence of such trials agents are typically chosen based on their ability to reduce triglyceride levels and based on their side effects. A number of drugs such as fibrates, <a href=\"topic.htm?path=vitamin-b3-niacin-drug-information\" class=\"drug drug_general\">niacin</a>, and statins reduce triglyceride levels (<a href=\"image.htm?imageKey=PC%2F75715\" class=\"graphic graphic_table graphicRef75715 \">table 5</a>); fibrates are the most potent. </p><p>The goal of therapy is to lower triglyceride levels below 886 <span class=\"nowrap\">mg/dL</span> (10.0 <span class=\"nowrap\">mmol/L)</span>. We aim for a triglyceride level below 500 <span class=\"nowrap\">mg/dL</span> in order to minimize large (two- to threefold increase) post-prandial elevations in triglyceride concentrations that may occur after a meal where fat, carbohydrate, or alcohol intake may be excessive.</p><p>Pharmacologic therapies vary in how quickly they reduce triglyceride levels. A response to fibrates is seen as early as two weeks into therapy with a maximal effect in six to eight weeks [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/87-89\" class=\"abstract_t\">87-89</a>]. We typically check triglyceride levels six to eight weeks after starting or altering therapy. The majority of the response with nicotinic acid is seen in six weeks and with fish oil in two weeks. </p><p>For the majority of patients with refractory hypertriglyceridemia there is a significant lifestyle component that requires management. Often the diet is suboptimal, the patients remain very overweight, or there is excessive alcohol or carbohydrate intake. </p><p>In these patients, combinations of fibrates, fish oil (n-3 fatty acids), and nicotinic acid are used but rarely. For recurrent pancreatitis due to hypertriglyceridemia, we advocate a strict reduction in refined carbohydrate, complete avoidance of alcohol, and caloric restriction to obtain an ideal body weight. In the setting of acute pancreatitis, plasma exchange is an option. </p><p class=\"headingAnchor\" id=\"H301366\"><span class=\"h3\">Fibrates</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fibrates available in the United States include <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> and fenofibrate. Other fibrates that are available worldwide include <a href=\"topic.htm?path=bezafibrate-united-states-not-available-drug-information\" class=\"drug drug_general\">bezafibrate</a> and ciprofibrate. Fibrate therapy can reduce triglyceride levels by as much as 50 percent or more [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/34\" class=\"abstract_t\">34</a>]. </p><p>Fibrates have been associated with muscle toxicity [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/90\" class=\"abstract_t\">90</a>], an effect that is more pronounced in patients also treated with a statin [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/91,92\" class=\"abstract_t\">91,92</a>]. This effect may be mediated by competitive inhibition of CYP3A4, leading to a reduction in statin metabolism (<a href=\"image.htm?imageKey=CARD%2F76992\" class=\"graphic graphic_table graphicRef76992 \">table 6</a>). <a href=\"topic.htm?path=pravastatin-drug-information\" class=\"drug drug_general\">Pravastatin</a> and <a href=\"topic.htm?path=fluvastatin-drug-information\" class=\"drug drug_general\">fluvastatin</a> are <strong>not</strong> extensively metabolized by the CYP3A4; as a result, they may be safer when combination therapy is required with a fibrate, but this is uncertain [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/93\" class=\"abstract_t\">93</a>]. (See <a href=\"topic.htm?path=statin-muscle-related-adverse-events#H107312605\" class=\"medical medical_review\">&quot;Statin muscle-related adverse events&quot;, section on 'Risk factors'</a>.) Glucuronidation, which is an important pathway for renal excretion of lipophilic statins, appears to be significantly inhibited by <a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">gemfibrozil</a> but not fenofibrate [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/94\" class=\"abstract_t\">94</a>]. In clinical studies, serum levels of statins increase 1.9- to 5.7-fold in gemfibrozil-treated subjects but are unchanged in fenofibrate-treated subjects. In the randomized trial of fenofibrate discussed above, there was a low incidence of myopathy whether or not patients were also taking a statin [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/78\" class=\"abstract_t\">78</a>]. Thus, fenofibrate is the preferred fibrate in patients who require combined therapy with a statin and fibrate [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/95,96\" class=\"abstract_t\">95,96</a>].</p><p>Fibrates also interfere with the metabolism of <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/91\" class=\"abstract_t\">91</a>]. As a result, the warfarin dose should be reduced by 30 percent in patients treated with this drug.</p><p>The following are the commonly used fibrates:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fenofibrate &ndash; Fenofibrate can be prescribed as a nanocrystal formulation (145 mg daily taken without regard to meals), as micronized capsules (200 mg daily taken with dinner), or as fenofibric acid (also called choline fenofibrate; 145 mg daily without regard to meals) [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/88\" class=\"abstract_t\">88</a>]. Prescribers should become familiar with one available formulation and follow prescribing information for that product.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=gemfibrozil-drug-information\" class=\"drug drug_general\">Gemfibrozil</a> &ndash; Gemfibrozil is prescribed at a dose of 600 mg twice daily.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=bezafibrate-united-states-not-available-drug-information\" class=\"drug drug_general\">Bezafibrate</a> &ndash; Bezafibrate is prescribed in doses of 200 mg three times daily or a sustained-release daily dose of 400 mg daily [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/97\" class=\"abstract_t\">97</a>]. </p><p/><p class=\"headingAnchor\" id=\"H301487\"><span class=\"h3\">Nicotinic acid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although nicotinic acid at doses of 1500 to 2000 mg daily can reduce triglyceride levels by 15 to 25 percent [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/34\" class=\"abstract_t\">34</a>], we rarely use it as monotherapy to reduce triglyceride levels as fibrates are more potent and have a better side effect profile. Nicotinic acid may worsen glucose tolerance in diabetic patients, although not all studies have found this effect [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/98-101\" class=\"abstract_t\">98-101</a>]. Glycemic control should be monitored carefully in diabetic patients treated with nicotinic acid. (See <a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">&quot;Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease&quot;</a>.) </p><p>Reductions in triglyceride levels are typically smaller with nicotinic acid than with fibrates, and there are data suggesting that nicotinic acid, particularly when used in combination with statin therapy, may have harmful effects. (See <a href=\"topic.htm?path=low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors#H3691238451\" class=\"medical medical_review\">&quot;Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors&quot;, section on 'Nicotinic acid (Niacin)'</a>.) Thus, we rarely use nicotinic acid in the management of hypertriglyceridemia. One exception might be a patient without diabetes who had refractory hypertriglyceridemia and was at high risk for pancreatitis or had a prior history of pancreatitis. </p><p class=\"headingAnchor\" id=\"H301630\"><span class=\"h3\">Fish oil</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fish oil supplements that contain eicosapentaenoic <span class=\"nowrap\">acid/docosahexaenoic</span> acid concentrate reduce VLDL production [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/102-104\" class=\"abstract_t\">102-104</a>] and can lower the serum triglyceride concentration by as much as 50 percent or more [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/103\" class=\"abstract_t\">103</a>]. However, their use is often limited by metabolic and gastrointestinal side effects. (See <a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements#H2\" class=\"medical medical_review\">&quot;Lipid lowering with diet or dietary supplements&quot;, section on 'Fish oil and omega-3 fatty acids'</a>.)</p><p>Active n-3 fatty acids constitute only 30 to 50 percent of many fish oil supplements. In comparison, a prescription preparation (Lovaza in the United States and Omacor elsewhere) is 85 percent omega-3 fatty acids. In patients with severe hypertriglyceridemia, Lovaza (4 <span class=\"nowrap\">g/day)</span> reduced triglyceride levels by 45 percent but raised LDL-C levels by 31 percent [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/105\" class=\"abstract_t\">105</a>]. Another commercial preparation, Vascepa, is more than 95 percent icosapent-ethyl, the ethyl ester of eicosapentaenoic acid [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/106\" class=\"abstract_t\">106</a>]. Icosapent-ethyl (4 <span class=\"nowrap\">g/day)</span> also reduced triglyceride levels by up to 45 percent, but did not significantly affect LDL-C levels [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/107\" class=\"abstract_t\">107</a>]. This differential effect on LDL-C levels appears large enough to be potentially clinically meaningful, but larger trials comparing preparations in appropriate target populations are needed before we can recommend this newer and more expensive preparation over dual omega-3 fatty acid products. Additionally, trials with clinical end points will help determine whether these LDL-C effects translate into differences in clinical outcomes.</p><p class=\"headingAnchor\" id=\"H301679\"><span class=\"h3\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been case reports of treating patients with marked symptoms with plasma <span class=\"nowrap\">exchange/plasmapheresis,</span> particularly in patients with acute pancreatitis [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/61,108\" class=\"abstract_t\">61,108</a>]. (See <a href=\"topic.htm?path=hypertriglyceridemia-induced-acute-pancreatitis#H9\" class=\"medical medical_review\">&quot;Hypertriglyceridemia-induced acute pancreatitis&quot;, section on 'Apheresis'</a>.)</p><p>An inhibitor of <em>APOC3</em> messenger RNA was found to decrease triglyceride levels in patients with chylomicronemia. (See <a href=\"#H3889979072\" class=\"local\">'Hereditary disorders'</a> above.) A randomized trial of this agent in patients with less severely elevated triglyceride levels demonstrated large reductions in levels both in patients not receiving other therapies and in patients also being treated with fibrates [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/109\" class=\"abstract_t\">109</a>]. Other emerging therapies for triglyceride lowering include ANGPLT3 inhibitors. </p><p class=\"headingAnchor\" id=\"H1231026640\"><span class=\"h1\">SCREENING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We screen adults for lipid abnormalities with a lipid profile, which includes a triglyceride level. In this setting, triglycerides are not the focal point of screening. (See <a href=\"topic.htm?path=screening-for-lipid-disorders-in-adults#H7832921\" class=\"medical medical_review\">&quot;Screening for lipid disorders in adults&quot;, section on 'Summary and recommendations'</a>.)</p><p>While hypertriglyceridemia is frequently an acquired disorder, many of the causes are familial. (See <a href=\"#H8\" class=\"local\">'Causes'</a> above.) Thus, we suggest screening first-degree relatives (by measuring a fasting triglyceride level) of patients with triglyceride levels above 500 <span class=\"nowrap\">mg/dL</span> (5.7 <span class=\"nowrap\">mmol/L)</span> who are otherwise healthy and have nothing to suggest an acquired disorder (eg, not obese, not diabetic, not hypothyroid). (See <a href=\"#H9\" class=\"local\">'Acquired disorders'</a> above.)</p><p class=\"headingAnchor\" id=\"H300925\"><span class=\"h1\">RECOMMENDATIONS OF OTHERS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The American College of <span class=\"nowrap\">Cardiology/American</span> Heart Association <a href=\"http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.full.pdf+html&amp;token=Zg4TC1Ue2puEb+kp3nS+ndOav8QNzPxWfVR8tddbSdYdV3Z56pKaTi2X+XERFqrMqOd/WIPPM6xmPrTCpAa2LIE942IKNFmFxE4kuJOtgTlp8aIvTJXq3UFd9ZzMBs+M&amp;TOPIC_ID=4570\" target=\"_blank\" class=\"external\">guidelines</a> recommend that adults with a triglyceride level &ge;500 <span class=\"nowrap\">mg/dL</span> (&ge;5.7 <span class=\"nowrap\">mmol/L)</span> be evaluated for secondary causes of hyperlipidemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/110\" class=\"abstract_t\">110</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We agree with recommendations made in the 2016 European Society of <span class=\"nowrap\">Cardiology/European</span> Atherosclerosis Society Guidelines for the Management of Dyslipidaemias [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/111\" class=\"abstract_t\">111</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We agree with recommendations made in the 2012 Endocrine Society (United States) guideline on the evaluation and treatment of hypertriglyceridemia [<a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/112\" class=\"abstract_t\">112</a>].</p><p/><p class=\"headingAnchor\" id=\"H2561744120\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-lipid-disorders-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Lipid disorders in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=high-triglycerides-the-basics\" class=\"medical medical_basics\">&quot;Patient education: High triglycerides (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=high-cholesterol-and-lipids-hyperlipidemia-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H302377\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>This topic refers to the range of fasting triglyceride levels from 150 to 499 <span class=\"nowrap\">mg/dL</span> (1.7 to 5.6 <span class=\"nowrap\">mmol/L)</span> as &quot;mild&quot; hypertriglyceridemia, &ge;500 to 886 <span class=\"nowrap\">mg/dL</span> (5.6 to 10.0 <span class=\"nowrap\">mmol/L</span> as &quot;moderate&quot; hypertriglyceridemia) and levels above 886 <span class=\"nowrap\">mg/dL</span> (10.0 <span class=\"nowrap\">mmol/L)</span> as &quot;severe&quot; hypertriglyceridemia. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated triglyceride levels are independently associated with cardiovascular risk, particularly coronary heart disease risk and the results of Mendelian Randomization studies make causality likely. (See <a href=\"#H3\" class=\"local\">'Triglycerides and CVD risk'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although it has not been convincingly shown that lowering triglyceride levels reduces risk, we believe it is reasonable to advise nonpharmacologic interventions such as weight loss in obese patients, aerobic exercise, avoidance of concentrated sugars and medications that raise serum triglyceride levels, and strict glycemic control in diabetics should be first-line therapy in patients with mild to moderate hypertriglyceridemia. Other risk factors for cardiovascular disease, such as hypertension and smoking, should also be addressed. Patients with more severe triglyceride elevations may need more aggressive nonpharmacologic interventions. (See <a href=\"#H723637349\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with triglyceride levels persistently above 886 <span class=\"nowrap\">mg/dL</span> (10.0 <span class=\"nowrap\">mmol/L)</span> after nonpharmacologic interventions, we suggest starting drug therapy to lower the risk of pancreatitis (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H1745689519\" class=\"local\">'Indications for drug therapy'</a> above.)</p><p/><p class=\"bulletIndent1\">We start therapy with a fibrate. (See <a href=\"#H301366\" class=\"local\">'Fibrates'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with hypertriglyceridemia not clearly associated with a secondary cause, we screen family members with a fasting triglyceride level. (See <a href=\"#H1231026640\" class=\"local\">'Screening'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/1\" class=\"nounderline abstract_t\">Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009; 169:572.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/2\" class=\"nounderline abstract_t\">Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/3\" class=\"nounderline abstract_t\">Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 2001; 87:1174.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/4\" class=\"nounderline abstract_t\">Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77:1179.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/5\" class=\"nounderline abstract_t\">Ballantyne CM, Grundy SM, Oberman A, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000; 85:2089.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/6\" class=\"nounderline abstract_t\">Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995; 6:209.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/7\" class=\"nounderline abstract_t\">Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16:697.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/8\" class=\"nounderline abstract_t\">Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/9\" class=\"nounderline abstract_t\">Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation 1996; 94:1913.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/10\" class=\"nounderline abstract_t\">Thompson WG, Gau GT. Hypertriglyceridemia and its pharmacologic treatment among US adults--invited commentary. Arch Intern Med 2009; 169:578.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/11\" class=\"nounderline abstract_t\">Rosenson RS, Davidson MH, Hirsh BJ, et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014; 64:2525.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/12\" class=\"nounderline abstract_t\">Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/13\" class=\"nounderline abstract_t\">Pare G, Anand SS. Mendelian randomisation, triglycerides, and CHD. Lancet 2010; 375:1584.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/14\" class=\"nounderline abstract_t\">Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med 2016; 374:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/15\" class=\"nounderline abstract_t\">Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Stitziel NO, Stirrups KE, et al. Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med 2016; 374:1134.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/16\" class=\"nounderline abstract_t\">Kersten S. The Genetics of Dyslipidemia--When Less Is More. N Engl J Med 2016; 374:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/17\" class=\"nounderline abstract_t\">Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015; 36:539.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/18\" class=\"nounderline abstract_t\">Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115:450.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/19\" class=\"nounderline abstract_t\">Tirosh A, Rudich A, Shochat T, et al. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007; 147:377.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/20\" class=\"nounderline abstract_t\">Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100:475.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/21\" class=\"nounderline abstract_t\">Sprecher DL, Pearce GL, Cosgrove DM, et al. Relation of serum triglyceride levels to survival after coronary artery bypass grafting. Am J Cardiol 2000; 86:285.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/22\" class=\"nounderline abstract_t\">Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/23\" class=\"nounderline abstract_t\">Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/24\" class=\"nounderline abstract_t\">Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999; 99:2901.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/25\" class=\"nounderline abstract_t\">Sprecher DL, Harris BV, Stein EA, et al. Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes. A preliminary report. Circulation 1996; 94:3239.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/26\" class=\"nounderline abstract_t\">Hypertriglyceridaemia and vascular risk. Report of a meeting of physicians and scientists, University College London Medical School. Lancet 1993; 342:781.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/27\" class=\"nounderline abstract_t\">Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998; 31:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/28\" class=\"nounderline abstract_t\">Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96:2520.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/29\" class=\"nounderline abstract_t\">Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/30\" class=\"nounderline abstract_t\">Horowitz BS, Goldberg IJ, Merab J, et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993; 91:1743.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/31\" class=\"nounderline abstract_t\">Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103:1191.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/32\" class=\"nounderline abstract_t\">F&ouml;ger B, Ritsch A, Doblinger A, et al. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996; 16:1430.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/33\" class=\"nounderline abstract_t\">Miller BD, Alderman EL, Haskell WL, et al. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/34\" class=\"nounderline abstract_t\">Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med 2007; 357:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/35\" class=\"nounderline abstract_t\">Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/36\" class=\"nounderline abstract_t\">Lamarche B, Tchernof A, Mauri&egrave;ge P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279:1955.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/37\" class=\"nounderline abstract_t\">Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60:473.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/38\" class=\"nounderline abstract_t\">Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 2001; 88:1370.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/39\" class=\"nounderline abstract_t\">DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/40\" class=\"nounderline abstract_t\">McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/41\" class=\"nounderline abstract_t\">Simpson HC, Mann JI, Meade TW, et al. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1:786.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/42\" class=\"nounderline abstract_t\">Humphries SE, Lane A, Green FR, et al. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14:193.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/43\" class=\"nounderline abstract_t\">Rosenson RS, Shott S, Lu L, Tangney CC. Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med 2001; 110:488.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/44\" class=\"nounderline abstract_t\">Mora S, Otvos JD, Rosenson RS, et al. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010; 59:1153.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/45\" class=\"nounderline abstract_t\">Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care 2015; 38:628.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/46\" class=\"nounderline abstract_t\">Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/47\" class=\"nounderline abstract_t\">O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998; 73:969.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/48\" class=\"nounderline abstract_t\">Smellie WS. Hypertriglyceridaemia in diabetes. BMJ 2006; 333:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/49\" class=\"nounderline abstract_t\">Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/50\" class=\"nounderline abstract_t\">Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/51\" class=\"nounderline abstract_t\">O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/52\" class=\"nounderline abstract_t\">Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166:950.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/53\" class=\"nounderline abstract_t\">Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/54\" class=\"nounderline abstract_t\">Fonarow GC, Deedwania P, Fonseca V, et al. Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. J Am Soc Hypertens 2009; 3:210.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/55\" class=\"nounderline abstract_t\">Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/56\" class=\"nounderline abstract_t\">Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 1996; 50:538.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/57\" class=\"nounderline abstract_t\">Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5:2073.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/58\" class=\"nounderline abstract_t\">Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J 2011; 5:49.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/59\" class=\"nounderline abstract_t\">Greenberg BH, Blackwelder WC, Levy RI. Primary type V hyperlipoproteinemia. A descriptive study in 32 families. Ann Intern Med 1977; 87:526.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/60\" class=\"nounderline abstract_t\">Ghiselli G, Schaefer EJ, Zech LA, et al. Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J Clin Invest 1982; 70:474.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/61\" class=\"nounderline abstract_t\">Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998; 27:551.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/62\" class=\"nounderline abstract_t\">Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123:59.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/63\" class=\"nounderline abstract_t\">Benlian P, De Gennes JL, Foubert L, et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996; 335:848.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/64\" class=\"nounderline abstract_t\">Nordestgaard BG, Abildgaard S, Wittrup HH, et al. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997; 96:1737.</a></li><li class=\"breakAll\">http://www.bbc.co.uk/news/health-20179561 (Accessed on November 19, 2012).</li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/66\" class=\"nounderline abstract_t\">Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371:2200.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/67\" class=\"nounderline abstract_t\">Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101:2777.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/68\" class=\"nounderline abstract_t\">Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999; 40:1933.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/69\" class=\"nounderline abstract_t\">Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med 1994; 120:1026.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/70\" class=\"nounderline abstract_t\">Huang Y, Rall SC Jr, Mahley RW. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler Thromb Vasc Biol 1997; 17:2817.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/71\" class=\"nounderline abstract_t\">Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/72\" class=\"nounderline abstract_t\">Gotto AM Jr. Hypertriglyceridemia: risks and perspectives. Am J Cardiol 1992; 70:19H.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/73\" class=\"nounderline abstract_t\">Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992; 37:249.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/74\" class=\"nounderline abstract_t\">Pownall HJ, Ballantyne CM, Kimball KT, et al. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. Arch Intern Med 1999; 159:981.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/75\" class=\"nounderline abstract_t\">Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37:13.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/76\" class=\"nounderline abstract_t\">Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011; 10:157.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/77\" class=\"nounderline abstract_t\">Lederle FA, Bloomfield HE. Drug treatment of asymptomatic hypertriglyceridemia to prevent pancreatitis: where is the evidence? Ann Intern Med 2012; 157:662.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/78\" class=\"nounderline abstract_t\">Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/79\" class=\"nounderline abstract_t\">Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102:21.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/80\" class=\"nounderline abstract_t\">Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/81\" class=\"nounderline abstract_t\">Deedwania PC, Hunninghake DB, Bays HE, et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005; 95:360.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/82\" class=\"nounderline abstract_t\">Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004; 15:115.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/83\" class=\"nounderline abstract_t\">Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275:128.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/84\" class=\"nounderline abstract_t\">Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/85\" class=\"nounderline abstract_t\">ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/86\" class=\"nounderline abstract_t\">Elam MB, Ginsberg HN, Lovato LC, et al. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiol 2017; 2:370.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/87\" class=\"nounderline abstract_t\">Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008; 6:1319.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/88\" class=\"nounderline abstract_t\">Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54:615.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/89\" class=\"nounderline abstract_t\">Capell WH, DeSouza CA, Poirier P, et al. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2003; 23:307.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/90\" class=\"nounderline abstract_t\">Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991; 151:1873.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/91\" class=\"nounderline abstract_t\">Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34:155.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/92\" class=\"nounderline abstract_t\">Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/93\" class=\"nounderline abstract_t\">Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/94\" class=\"nounderline abstract_t\">Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003; 163:2394.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/95\" class=\"nounderline abstract_t\">Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/96\" class=\"nounderline abstract_t\">Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009; 103:515.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/97\" class=\"nounderline abstract_t\">Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 1987; 33:539.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/98\" class=\"nounderline abstract_t\">Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264:723.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/99\" class=\"nounderline abstract_t\">Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994; 121:252.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/100\" class=\"nounderline abstract_t\">Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284:1263.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/101\" class=\"nounderline abstract_t\">Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162:1568.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/102\" class=\"nounderline abstract_t\">Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74:82.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/103\" class=\"nounderline abstract_t\">Harris WS, Connor WE, Illingworth DR, et al. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 1990; 31:1549.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/104\" class=\"nounderline abstract_t\">Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85:544.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/105\" class=\"nounderline abstract_t\">Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4:385.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/106\" class=\"nounderline abstract_t\">Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/107\" class=\"nounderline abstract_t\">Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011; 108:682.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/108\" class=\"nounderline abstract_t\">Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 1999; 3:227.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/109\" class=\"nounderline abstract_t\">Gaudet D, Alexander VJ, Baker BF, et al. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med 2015; 373:438.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/110\" class=\"nounderline abstract_t\">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/111\" class=\"nounderline abstract_t\">Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37:2999.</a></li><li><a href=\"https://www.uptodate.com/contents/hypertriglyceridemia/abstract/112\" class=\"nounderline abstract_t\">Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2969.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4570 Version 40.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H302377\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H823705211\" id=\"outline-link-H823705211\">INDICATIONS FOR MEASUREMENT</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DEFINITION AND PREVALENCE</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">TRIGLYCERIDES AND CVD RISK</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">CAUSES</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Acquired disorders</a></li><li><a href=\"#H3889979072\" id=\"outline-link-H3889979072\">Hereditary disorders</a></li></ul></li><li><a href=\"#H248234180\" id=\"outline-link-H248234180\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H3925892135\" id=\"outline-link-H3925892135\">DIAGNOSTIC APPROACH</a></li><li><a href=\"#H723637349\" id=\"outline-link-H723637349\">MANAGEMENT</a><ul><li><a href=\"#H2126114411\" id=\"outline-link-H2126114411\">Lifestyle modifications</a></li><li><a href=\"#H1745689519\" id=\"outline-link-H1745689519\">Indications for drug therapy</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Pharmacologic therapy</a><ul><li><a href=\"#H301366\" id=\"outline-link-H301366\">- Fibrates</a></li><li><a href=\"#H301487\" id=\"outline-link-H301487\">- Nicotinic acid</a></li><li><a href=\"#H301630\" id=\"outline-link-H301630\">- Fish oil</a></li><li><a href=\"#H301679\" id=\"outline-link-H301679\">- Other</a></li></ul></li></ul></li><li><a href=\"#H1231026640\" id=\"outline-link-H1231026640\">SCREENING</a></li><li><a href=\"#H300925\" id=\"outline-link-H300925\">RECOMMENDATIONS OF OTHERS</a></li><li><a href=\"#H2561744120\" id=\"outline-link-H2561744120\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H19\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H302377\" id=\"outline-link-H302377\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PC/4570|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/67263\" class=\"graphic graphic_figure\">- TG LDL HDL and coronary risk</a></li></ul></li><li><div id=\"PC/4570|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PC/76826\" class=\"graphic graphic_picture\">- Hypertriglyceride milky plasma</a></li><li><a href=\"image.htm?imageKey=PC/82268\" class=\"graphic graphic_picture\">- Eruptive xanthomata forearm</a></li><li><a href=\"image.htm?imageKey=PC/78663\" class=\"graphic graphic_picture\">- Tuberoeruptive xanthomata</a></li><li><a href=\"image.htm?imageKey=PC/58173\" class=\"graphic graphic_picture\">- Striate palmar xanthomata</a></li></ul></li><li><div id=\"PC/4570|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PC/106983\" class=\"graphic graphic_table\">- Causes of elevated triglycerides</a></li><li><a href=\"image.htm?imageKey=CARD/54329\" class=\"graphic graphic_table\">- Fredrickson classification of lipid disorders</a></li><li><a href=\"image.htm?imageKey=PC/71978\" class=\"graphic graphic_table\">- Glycemic index and load values</a></li><li><a href=\"image.htm?imageKey=PC/79454\" class=\"graphic graphic_table\">- Fish servings for EPA DHA</a></li><li><a href=\"image.htm?imageKey=PC/75715\" class=\"graphic graphic_table\">- Effects of lipid lowering drugs on serum lipids</a></li><li><a href=\"image.htm?imageKey=CARD/76992\" class=\"graphic graphic_table\">- Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antihypertensive-drugs-and-lipids\" class=\"medical medical_review\">Antihypertensive drugs and lipids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiovascular-benefits-and-risks-of-moderate-alcohol-consumption\" class=\"medical medical_review\">Cardiovascular benefits and risks of moderate alcohol consumption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiovascular-disease-risk-assessment-for-primary-prevention-our-approach\" class=\"medical medical_review\">Cardiovascular disease risk assessment for primary prevention: Our approach</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-acute-pancreatitis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of acute pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-xanthomas\" class=\"medical medical_review\">Cutaneous xanthomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-cardiovascular-disease-and-risk-factors-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology of cardiovascular disease and risk factors in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=etiology-of-acute-pancreatitis\" class=\"medical medical_review\">Etiology of acute pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypertriglyceridemia-induced-acute-pancreatitis\" class=\"medical medical_review\">Hypertriglyceridemia-induced acute pancreatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inherited-disorders-of-ldl-cholesterol-metabolism-other-than-familial-hypercholesterolemia\" class=\"medical medical_review\">Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=insulin-resistance-definition-and-clinical-spectrum\" class=\"medical medical_review\">Insulin resistance: Definition and clinical spectrum</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipid-abnormalities-in-nephrotic-syndrome\" class=\"medical medical_review\">Lipid abnormalities in nephrotic syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipid-abnormalities-in-thyroid-disease\" class=\"medical medical_review\">Lipid abnormalities in thyroid disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipid-lowering-with-diet-or-dietary-supplements\" class=\"medical medical_review\">Lipid lowering with diet or dietary supplements</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lipoprotein-classification-metabolism-and-role-in-atherosclerosis\" class=\"medical medical_review\">Lipoprotein classification, metabolism, and role in atherosclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=low-density-lipoprotein-cholesterol-lowering-with-drugs-other-than-statins-and-pcsk9-inhibitors\" class=\"medical medical_review\">Low density lipoprotein cholesterol lowering with drugs other than statins and PCSK9 inhibitors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">Major side effects of systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-elevated-low-density-lipoprotein-cholesterol-ldl-c-in-primary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">Management of elevated low density lipoprotein-cholesterol (LDL-C) in primary prevention of cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-low-density-lipoprotein-cholesterol-ldl-c-in-secondary-prevention-of-cardiovascular-disease\" class=\"medical medical_review\">Management of low density lipoprotein cholesterol (LDL-C) in secondary prevention of cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=managing-the-side-effects-of-tamoxifen\" class=\"medical medical_review\">Managing the side effects of tamoxifen</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=maternal-adaptations-to-pregnancy-endocrine-and-metabolic-changes\" class=\"medical medical_review\">Maternal adaptations to pregnancy: Endocrine and metabolic changes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=measurement-of-blood-lipids-and-lipoproteins\" class=\"medical medical_review\">Measurement of blood lipids and lipoproteins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=menopausal-hormone-therapy-and-cardiovascular-risk\" class=\"medical medical_review\">Menopausal hormone therapy and cardiovascular risk</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris\" class=\"medical medical_review\">Oral isotretinoin therapy for acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-established-risk-factors-for-cardiovascular-disease\" class=\"medical medical_review\">Overview of established risk factors for cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-primary-prevention-of-coronary-heart-disease-and-stroke\" class=\"medical medical_review\">Overview of primary prevention of coronary heart disease and stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-secondary-prevention-of-ischemic-stroke\" class=\"medical medical_review\">Overview of secondary prevention of ischemic stroke</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overweight-and-obesity-in-adults-health-consequences\" class=\"medical medical_review\">Overweight and obesity in adults: Health consequences</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-cholesterol-and-lipids-hyperlipidemia-beyond-the-basics\" class=\"medical medical_patient\">Patient education: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-triglycerides-the-basics\" class=\"medical medical_basics\">Patient education: High triglycerides (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risks-and-side-effects-associated-with-estrogen-progestin-contraceptives\" class=\"medical medical_review\">Risks and side effects associated with estrogen-progestin contraceptives</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=screening-for-lipid-disorders-in-adults\" class=\"medical medical_review\">Screening for lipid disorders in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-lipid-disorders-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Lipid disorders in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=statin-muscle-related-adverse-events\" class=\"medical medical_review\">Statin muscle-related adverse events</a></li></ul></div></div>","javascript":null}